JamesABonnerMD
Radiation Oncology • Birmingham, ALProfessor of Radiation Oncology, University Alabama
Are you Dr. Bonner?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 67 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
619 19th St S
Birmingham, AL 35233Phone+1 205-934-6600
Summary
- Dr. James Bonner, MD is a radiation oncologist in Birmingham, Alabama. He is currently licensed to practice medicine in Alabama, Texas, and Arizona. He is affiliated with Children's of Alabama, Cooper Green Hospital, and Birmingham VA Medical Center.
Education & Training
University of MichiganResidency, Radiation Oncology, 1986 - 1990
Henry Ford Health/Henry Ford HospitalInternship, Transitional Year, 1985 - 1986
Wayne State University School of MedicineClass of 1985
Certifications & Licensure
MI State Medical License 1990 - 2027
AZ State Medical License 1995 - 2026
FL State Medical License 1995 - 2026
AL State Medical License 1998 - 2025
MN State Medical License 1991 - 2025
TX State Medical License 1997 - 2025- American Board of Radiology Radiation Oncology
Clinical Trials
- Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III or Stage IV Cancer of the Oropharynx, Hypopharynx, or Larynx Start of enrollment: 1999 Apr 01
- Radiation Therapy in Preventing Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer Start of enrollment: 2002 Sep 01
- Bevacizumab, Cisplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer Start of enrollment: 2006 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- HIF1α-regulated glycolysis promotes activation-induced cell death and IFN-γ induction in hypoxic T cells.Hongxing Shen, Oluwagbemiga A Ojo, Haitao Ding, Logan J Mullen, Chuan Xing
Nature Communications. 2024-10-30 - 1 citationsSurrogate endpoints in clinical trials of p16-positive squamous cell carcinoma of the oropharynx: an individual patient data meta-analysis.Laila A Gharzai, Emily Morris, Krithika Suresh, Phuc Felix Nguyen-Tân, David I Rosenthal
The Lancet. Oncology. 2024-03-01 - HIF1α-glycolysis engages activation-induced cell death to drive IFN-γ induction in hypoxic T cells.Hongxing Shen, Logan Mullen, Oluwagbemiga A Ojo, Chuan Xing, Abdelrahman Yassin
Research Square. 2024-01-12
Press Mentions
Varian Medical : Alabama's Only Proton Therapy Center Treats First Patient with Varian ProBeamMarch 17th, 2020
The Proton International at UAB Facility Treats First Patient with Proton TherapyMarch 14th, 2020
Grant Support
- Radiosensitization With Recombinant Antibodies To EGFRNational Cancer Institute2002–2005
- Proliferative Response To Radiation And EtoposideNational Cancer Institute1998–2001
- Radiation Therapy VS Anti EGFR Antibody C225 In SCCNational Center For Research Resources2000
- Proliferative Response To Radiation And EtoposideNational Cancer Institute1997–1998
Professional Memberships
- Member
